There were larger between-group effect sizes for anxiety disorders than depressive disorders, but this was mainly driven by the placebo response, which was larger with the latter. The risk of serious adverse events was higher in those treated with an antidepressant compared with placebo (RR 1.76; 95% CI 1.34-2.32; P <0.001). The magnitude of the effect and adverse event profiles were disorder dependent. The authors conclude that “there is some evidence for the benefit of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors in children and adolescents, but owing to the higher risk for severe adverse events, a cautious and individual cost-benefit analysis is of importance.”